gip/glp 1-agonist tirzepatide GLP-1/GIP dual agonist normalizes diabetic nephropathy via PI3K/AKT mediated suppression of oxidative stress Tirzepatide, a dual GIP/GLP-1 receptor

If diarrhea persists beyond a few days at any dose level, it may indicate that the dose escalation happened too quickly

The study met both the co-primary endpoint and all key secondary endpoints compared to placebo

Molecules, 27 (13), 4315

tirzepatide more commonly causes diarrhea, with much less nausea

Research models suggest it may interact with: GLP-1 receptors GIP receptors glucagon receptors This additional glucagon receptor activity is one of the major distinctions researchers evaluate when comparing Retatrutide vs Tirzepatide

If you are switching from a 10 mg/mL vial to a 20 mg/mL vial at this point, remember that your unit draw changes from 100 to 50